Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Current Pharmaceutical Design|October 6, 2006
Pharmacogenomics of asthmaAndreas Pahl, Ewald Benediktus, Ligia ChialdaCytometry. Part a : the Journal of the International Society for Analytical Cytology|April 2, 2021
Basophil activation test: Assay precision and BI 1002494 SYK inhibition in healthy and mild asthmaticsSaskia Carstensen, Ewald Benediktus, Tobias Litzenburger, et al.Journal of Clinical Pharmacology|June 14, 2017
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled AsthmaAndy Fowler, Rüdiger Koenen, James Hilbert, et al.European Journal of Pharmacology|December 19, 2006
Lipopolysaccharide-induced lung inflammation is inhibited by neutralization of GM-CSFRuzica Puljic, Ewald Benediktus, Christine Plater-Zyberk, et al.British Journal of Clinical Pharmacology|October 13, 2020
Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjectsYasuhiro Tsuda, Christine Grimaldi, Fenglei Huang, et al.Pulmonary Pharmacology & Therapeutics|January 4, 2011
TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airwaysMatthias J Duechs, Christian Hahn, Ewald Benediktus, et al.British Journal of Pharmacology|February 7, 2026
Safety, tolerability, pharmacokinetics and pharmacodynamics of the spleen tyrosine kinase inhibitor BI 894416 in healthy volunteers and patients with asthmaSaskia Carstensen-Aurèche, Tobias Litzenburger, Dorothy De Sousa, et al.British Journal of Clinical Pharmacology|September 28, 2020
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteersTobias Litzenburger, Jürgen Steffgen, Ewald Benediktus, et al.Pageof 1